Location History:
- Boston, MA (US) (2019)
- Cleveland, OH (US) (2016 - 2022)
Company Filing History:
3 out of 1,039 
2 out of 443 
2 out of 1,209 
Years Active: 2016-2022
Title: Innovations in Cancer Treatment by Inventor Mohamed Abazeed
Introduction
Inventor Mohamed Abazeed, based in Cleveland, Ohio, has made significant contributions to the field of cancer treatment, holding a total of five patents. His work primarily focuses on the intersection of machine learning and radiotherapy, aiming to personalize treatment for patients based on their unique genetic and physiological characteristics.
Latest Patents
Abazeed's latest innovations include a decision support system for individualizing radiotherapy dose. This invention leverages machine learning to generate predictions of outcomes tailored to individual patients, determining optimal dosage that minimizes side effects and the risk of treatment failure. His second noteworthy patent, Genospecific Radiosensitization, involves a method of treating cancer patients by characterizing their radiation-susceptibility through the detection of mutations in an NRF2 pathway protein. This approach allows healthcare providers to customize treatment plans, deciding between standard radiation therapy and the use of radiosensitizing agents based on the patient's genetic profile.
Career Highlights
Throughout his career, Mohamed Abazeed has worked with renowned institutions such as the Cleveland Clinic Foundation and the Broad Institute, Inc. These experiences have enriched his expertise in cancer treatment and reinforced his commitment to leveraging innovative technology for better health outcomes.
Collaborations
Abazeed has collaborated with esteemed professionals like Matthew Meyerson and Drew Adams, pooling their expertise to advance cancer research and treatment methodologies. Together, they contribute to a multidisciplinary approach that seeks to optimize patient care and improve therapeutic effectiveness.
Conclusion
Mohamed Abazeed exemplifies the spirit of innovation in the medical field. With his groundbreaking patents and collaborative efforts, he is at the forefront of developing personalized cancer treatments that harness the power of machine learning and genetic profiling. His work not only enhances patient outcomes but also pushes the boundaries of what is possible in modern medicine.